Search Results for “EC” – Page 620 – media

Pear Therapeutics Wins FDA Nod for the First-Ever Medical App for Treating Drug Addiction

The U.S. Food and Drug Administration(FDA) permitted marketing of the first mobile medical application to help treat substance use disorders (SUD). The Reset application is intended to be used with outpatient therapy to treat alcohol, cocaine, marijuana and stimulant SUDs. The application is not intended to be used to treat opioid dependence.
- Source: Biospace
- 626
- September 18, 2017
FDA substance use disorders
FDA approves first cancer biosimilar

The US Food and Drug Administration(FDA) has approved Amgen’s Mvasi (bevacizumab-awwb) as a biosimilar to Roche/Genentech’s Avastin (bevacizumab) for the treatment of multiple types of cancer, making it the first biosimilar approved in the country for the treatment of cancer.
- Source: Pharmatimes
- 679
- September 18, 2017
biosimilar cancer FDA New Approvals
How to Write a Development Letter to Clients after an Exhibition

After attending Shanghai CNEF and Hospitalar in Brazil you come home and look at the pile of name cards and the masses of client information you collected. Now what? We often establish new business relationships at exhibitions such as these but the key of securing them lies in how you follow up on your clients. Ddu (www.drugdu.com), the leading global pharmaceutical and medical device B2B online platform, today shares with you some insight on how to organize client materials and write your first follow up development letter. I. Organize and follow up on your clients with purpose The first step is to collect as much information as possible and pay special attention to all the relevant details at the exhibition. For example, what the client is looking for, what they are most concerned about, what kind of products and suppliers they have in mind and which business partners they would like to keep. After this you will be able to arrange the information according to clients’ interests ...
- Source: Ddu
- 887
- September 18, 2017
Ddu College development letter
Medtronic launches new surgical navigation system for ENT procedures

Medtronic has launched a new surgical navigation system named as StealthStation ENT to help surgeons in treating conditions within the ear, nose, and throat (ENT) anatomy.
- Source: medicaldevices-business-review
- 726
- September 15, 2017
Company Insight ENT surgical
Cancer Startup Torque Therapeutics Nabs $21 Million and Sets Up Shop in Kendall Square

Torque Therapeutics has come out of stealth mode to launch with a $21 million Series A financing. It is looking to raise another $14 million, according to its filing with the U.S. Securities and Exchange Commission (SEC).
- Source: Biospace
- 809
- September 15, 2017
cell immune Series therapy
China’s Import and Export Report of Surgical Instruments

According to a global statistics report on medical devices, the global surgical instruments market has witnessed a drastic growth spurt in the past 8 years. In 2010, global sales of surgical instruments reached 12 billion USD, 12.9 billion USD in 2011 and 18.6 billion USD in 2014.
- Source: Ddu
- 2,960
- September 15, 2017
export import Market Reports surgical
Medical Trade Exhibitions in September — Global Product Promotions from the Comfort of Your Own Home!

Since the launch of the Ddu Global Promotion Plan, Ddu has succeeded in helping users do international product promotions without leaving home and has matched thousands of orders, rapidly gaining popularity in the medical trade industry. The upcoming exhibitions of Ddu’s Global Promotion Plan include Thailand, Vietnam, Azerbaijan and Argentina!
- Source: Ddu
- 606
- September 15, 2017
Argentina Azerbaijan Exhibitions & Activities Thailand
FDA grants fast-track designation for Shire’s lung drug

The FDA has granted Fast Track designation to Shire's SHP607 for the prevention of chronic lung disease in extremely premature infants.
- Source: Pharmatimes
- 578
- September 14, 2017
chronic Clinical lung New Approvals
Boehringer collaborates with Gubra to develop next generation obesity treatments

Germany based Boehringer Ingelheim has committed up to €250 million ($300 million) to work with Gubra on obesity treatments. As per the deal, Boehringer can access Gubra’s expertise in the design, synthesis and preclinical testing of therapeutic peptides.
- Source: Biospectrumasia
- 482
- September 14, 2017
cardiometabolic Market Views obesity
Teva Announces Sale of PARAGARD® (intrauterine copper contraceptive) to CooperSurgical

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced it has entered into a definitive agreement under which CooperSurgical will acquire PARAGARD® (intrauterine copper contraceptive), a product within its global Women’s Health business, in a $1.1 billion cash transaction. PARAGARD® had revenues of approximately $168 million for the trailing twelve month period ending June 30, 2017. This transaction includes Teva’s manufacturing facility in Buffalo, NY, which produces PARAGARD® exclusively.
- Source: finance.yahoo
- 527
- September 13, 2017
Company Insight Market Views oncology PARAGARD

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.